NASDAQ$TPST
Tempest Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Tempest reported year-end financial results and provided a business update.
Tempest Therapeutics reported positive data for TPST-1120 in liver cancer and is preparing for a pivotal Phase 3 trial. The company ended the year with $39.2 million in cash and cash equivalents.
- Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of care.
- Reported new biomarker data in two important subpopulations, PD-L1 negative and b-catenin mutant patients, consistent with MoA of TPST-1120.
- Preparing to move TPST-1120 into a pivotal Phase 3 trial in HCC and TPST-1495 into a Phase 2 in FAP.
- Tempest expected to have sufficient resources to fund operations into the second quarter of 2025.
Headline financials
Revenue & EPS history
Tempest · Revenue · Quarterly
$0
Forward guidance
Tempest plans to advance TPST-1120 into a registrational study in first-line liver cancer patients, subject to obtaining feedback from the FDA. Expect to report data from the combination arm at the two highest TPST-1495 doses in patients with advanced endometrial cancer in 2024.
Tailwinds
- Expect to announce updated data from the ongoing randomized study in first-line liver cancer patients in 2024.
- Plan to advance TPST-1120 into a registrational study in first-line liver cancer patients, subject to obtaining feedback from the FDA.
- Plan to advance TPST-1495 into a Phase 2 study in patients with Familial Adenomatous Polyposis (“FAP”) under the auspices of the Cancer Prevention Clinical Trials Network and funded by the National Cancer Institute (“NCI”) Division of Cancer Prevention in 2024, subject to final approval of NCI.
- Expect to report data from the combination arm at the two highest TPST-1495 doses in patients with advanced endometrial cancer in 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-2.1%
Avg return
Earnings day
-3.1%
Avg return
5 days after
-10.2%
Avg return
30 days after
34%
12 / 35 earnings
Positive
+15.8%
Q2 2022
Best reaction
-41.3%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +1.2% | +4.5% | -36.2% | |
| Q3 2025 | -3.2% | -3.3% | -68.6% | |
| Q2 2025 | +10.0% | +31.5% | +33.7% | |
| Q1 2025 | -2.6% | -8.2% | +0.7% | |
| Q4 2024 | +5.9% | -9.5% | -28.9% | |
| Q3 2024 | -11.5% | -19.1% | -24.1% | |
| Q2 2024 | -16.8% | -21.4% | -11.4% | |
| Q1 2024 | -5.5% | -2.0% | -10.4% | |
| Q4 2023 | -3.1% | -5.9% | -18.1% | |
| Q3 2023 | +6.1% | +11.7% | +3.6% | |
| Q2 2023 | +7.2% | +13.5% | -29.1% | |
| Q1 2023 | +3.4% | +6.3% | -42.0% | |
| Q4 2022 | +10.2% | +8.1% | +80.3% | |
| Q3 2022 | -12.1% | -11.5% | -14.0% | |
| Q2 2022 | +15.8% | +18.2% | +5.1% | |
| Q1 2022 | +5.9% | +12.9% | -2.2% | |
| Q4 2021 | -3.6% | -18.8% | -12.4% | |
| Q3 2021 | -2.5% | -7.8% | -35.5% | |
| Q2 2021 | -0.1% | -6.3% | +6.3% | |
| Q1 2021 | -0.8% | -1.6% | -10.2% | |
| Q4 2020 | -41.3% | -41.7% | -46.3% | |
| Q3 2020 | -1.3% | -1.3% | +28.2% | |
| Q2 2020 | -2.6% | -3.6% | -17.7% | |
| Q1 2020 | -4.7% | +0.0% | +32.0% | |
| Q3 2019 | -2.7% | +1.2% | -21.1% | |
| Q2 2019 | -0.5% | -7.4% | -23.2% | |
| Q1 2019 | +2.6% | +0.9% | -21.2% | |
| Q3 2018 | -5.2% | -13.0% | -10.0% | |
| Q2 2018 | -14.4% | -8.9% | -15.6% | |
| Q1 2018 | +0.7% | +0.7% | -4.7% | |
| Q3 2017 | -4.6% | -2.9% | -0.7% | |
| Q2 2017 | +3.1% | -2.5% | -12.3% | |
| Q1 2017 | -0.4% | -1.8% | -8.1% | |
| Q3 2016 | -6.8% | -31.6% | -35.4% | |
| Q2 2016 | -0.5% | +11.2% | +12.7% | |
| Q1 2016 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro